As of Thursday close, Relay Therapeutics Inc.’s (NASDAQ:RLAY) stock was up $0.45, moving up 2.95 percent to $15.72. The average number of shares traded per day over the past five days has been 1,888,780 shares. 1 time new highs have been achieved over the past 5 days, with a -$7.58 fall in that time frame. In the last twenty days, the average volume was 895,700, while in the previous 50 days, it was 745,342.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, RLAY stock retreated -49.68%. Shares of the company fell to $14.37 on 05/11/22, the lowest level in the past month. A 52-week high of $38.60 was reached on 04/04/22 after having rallying from a 52-week low of $14.37. Since the beginning of this year, RLAY’s stock price has dropped by -48.81% or -$14.99, and marked a new high 3 times. However, the stock has declined by -59.28% since its 52-week high.
Relay Therapeutics Inc. (RLAY) last reported insider trading activity 11 days ago on May 02. Bergstrom Donald A, the President, R&D of the company, disposed of 13,000 shares for $24.62 on May 02. It resulted in a $320,060 divestment by the insider. Bergstrom Donald A sold 1,811 shares at an average price of $25.57 on Apr 28. The insider now owns 92,493 shares following the transaction. On Apr 28, Chief Administrative Officer Porter Andy sold 435 shares at $25.57 apiece. The transaction was valued at $11,123.
In the three months ended September 29, Relay Therapeutics Inc.’s quick ratio stood at 22.00, while its current ratio was 22.00, showing that the company is able to pay off its debt. Based on annual data, RLAY earned $367.73 million in gross profit and brought in $3.03 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. RLAY’s revenue rose 100.0% to $0.67 million during the quarter, while net income inched up to $27.83 million. While analysts expected Relay Therapeutics Inc. to report -$0.64 quarterly earnings, the actual figure was -$0.66 per share, beating the consensus estimate by -3.10%. During the quarter, the company generated -$66.01 million in EBITDA. The liabilities of Relay Therapeutics Inc. were 110.64 million at the end of its most recent quarter ended September 29, and its total debt was $23.31 million. The value of shareholders’ equity is $108.28 million.
This quick technical analysis looks at Relay Therapeutics Inc.’s (RLAY) price momentum. With a historical volatility rate of 109.54%, the RSI 9-day stood at 19.79% on 12 May.
With respect to its five-day moving average, the current Relay Therapeutics Inc. price is down by -32.53% percent or -$7.58. At present, RLAY shares trade -51.30% below its 20-day simple moving average and -46.18% percent below its 100-day simple moving average. However, the stock is currently trading approximately -33.78% below its SMA50 and -52.48% below its SMA200.
Stochastic coefficient K was 6.27% and Stochastic coefficient D was 5.37%, while ATR was 2.79. Given the Stochastic reading of 8.75% for the 14-day period, the RSI (14) reading has been calculated as 26.32%. As of today, the MACD Oscillator reading stands at -4.50, while the 14-day reading stands at -6.57.
Berenberg launched its rating on Relay Therapeutics Inc. (NASDAQ: RLAY) to a Buy in a note to investors on February 01, 2022. Relay Therapeutics Inc. (RLAY) has been rated Buy by analysts. According to 0 brokerage firms, RLAY is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Relay Therapeutics Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $46.00, the current consensus forecast for the stock is $35.00 – $49.00. Based on these forecasts, analysts predict Relay Therapeutics Inc. (RLAY) will achieve an average price target of $44.86.